Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis
Both diabetes and antidiabetic drugs (ADDs) increase the risk for cardiovascular (CV) diseases. Due to the increasing concern about CV safety associated with ADDs, the US FDA revised regulatory guidelines in 2008 to include CV safety as an endpoint.
The objective of the current study was to conduct a systematic review with meta-analysis to compare CV mortality of oral ADDs approved before and after the FDA’s 2008 guidance.
Three electronic databases (PubMed, Scopus, and the Clinical Trial Registry) were searched to retrieve studies published up to 24 February 2017. Randomized clinical trials were included in this study if they (1) were published in the English language; (2) included adults with type 2 diabetes mellitus with or without CV risk factors, who were taking at least one oral antidiabetic drug; and (3) had at least one study outcome as CV mortality. Meta-analysis was performed using a random-effects model. Small-study effects were accessed using funnel plot symmetry. The primary outcome was CV mortality.
We found that there was no significant increase in CV mortality for drugs approved before and after 2008. The overall odds ratio (OR) and the upper bound of the two-sided 95% confidence interval (CI) for all drugs approved after 2008 (OR 0.74, 95% CI 0.52–1.07) were lower than the overall OR for all drugs approved before 2008 (OR 1.03, 95% CI 0.89–1.19). In addition, the upper bounds of the two-sided 95% CI for both groups of drugs before and after 2008 were below 1.3. Empagliflozin, which was approved after the guidance, was significantly associated with a reduction in CV mortality.
The 2008 FDA guidance appears to have a positive impact on CV risk assessment of recently marketed drugs for the management of diabetes.
Compliance with Ethical Standards
No funding was received to conduct this study.
Conflicts of interest
Rashmi Goyat, Pragya Rai, Jongwha Chang, Charles D. Ponte, and Xi Tan declare no conflicts of interest.
- 1.National Diabetes Statistics Report. Atlanta: Centers for Disease Control and Prevention; 2014Google Scholar
- 3.Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta: Centers for Disease Control and Prevention; 2011.Google Scholar
- 4.Standards of medical care in diabetes—2016: summary of revisions. Diabetes Care. 2016;39(Suppl 1):S4–5Google Scholar
- 5.Ryden L, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88–136.PubMedGoogle Scholar
- 6.Skyler JS, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119(2):351–7.CrossRefPubMedGoogle Scholar
- 11.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.Google Scholar
- 23.Guidance for Industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Available at: https://www.fda.gov/downloads/Drugs/.../Guidances/ucm071624.pdf. Accessed 12 Mar 2018.
- 40.McGuire DK. Regulating drugs that regulate glucose: cardiovascular assessment of type 2 diabetes medications. Dallas: University of Texas Southwestern Medical Center; 2014.Google Scholar